Vifor Pharma AG
VIFN.S- Latest Trade
- trading higher171.95CHF
- Change
- 0.25
- % Change
0.15%Positive
- Day Range
- 171.35 - 175.10
- 52-Week Range
- 102.30 - 197.20
As of Jun 25 2022. Values delayed up to 15 minutes
- Previous Close
- 171.70
- Open
- 171.35
- Volume
- 5,870.00
- 3 Month Average Trading Volume
- 1.16
- Shares Out (Mil)
- 64.89
- Market Cap
- 11,160.50
- Forward P/E
- 31.79
- Dividend Yield
- 1.16
Key Statistics
3 mean rating - 9 analysts
- P/E Excl. Extra Items (TTM)
- 76.25
- Price To Sales (TTM)
- 6.36
- Price To Book (Quarterly)
- 3.19
- Price To Cash Flow (Per Share TTM)
- 23.72
- Total Debt/Total Equity (Quarterly)
- 17.30
- Long Term Debt/Equity (Quarterly)
- 3.35
- Return On Investment (TTM)
- 6.75
- Return On Equity (TTM)
- 5.15
2021 (millions USD)
About Vifor Pharma AG
Company Information
Vifor Pharma AG, formerly known as Galenica AG, is a Switzerland-based company engaged in the healthcare market. The Company operates through a single pharmaceutical segment. It develops, manufactures and markets pharmaceutical products, specializing in therapies for iron deficiency, nephrology and cardio-renal diseases. The Company's portfolio of iron deficiency treatments includes intravenous products, Ferinject and Venofer, and oral product, Maltofer, among others. Its portfolio of renal pharmaceuticals includes products for anaemia management, such as Mircera, mineral and bone management, such as Velphoro, Rayaldee and Osvaren, and cardio-renal management, such as patiromer (in the United States sold under the brand Veltassa). The Company also conducts research in the area of infectious and rare diseases, partnering with other biopharmaceutical companies. The Company has production sites in Switzerland and Portugal as well as a network of affiliates and partners around the world.
Address
Rechenstrasse 37ST. GALLEN,
9014
Switzerland
Industry
Biotechnology & Drugs
Executive Leadership
- Jacques Theurillat
- Independent Chairman of the Board of Directors
- Abbas Hussain
- Chief Executive Officer
- Romeo Cerutti
- Independent Vice Chairman of the Board
- Michael Puri
- Chief Human Resource Officer, Member of the Executive Committee
- Barbara Angehrn
- Chief Business Officer, Member of the Executive Committee
- Herve Gisserot
- Member of the Executive Committee, Chief Commercial Officer
- Klaus Henning Jensen
- Chief Medical Officer, Member of the Executive Committee
- Christoph Springer
- Chief Strategy Officer, Member of the Executive Committee
- Andreas Walde
- General Secretary and Secretary to the Board of Directors
- Michel Burnier
- Independent Directors
- Alexandre P. Lebeaut
- Independent Director
- Sue Mahony
- Independent Directors
- Asa Riisberg
- Independent Director
- Kim Stratton
- Independent Director
Latest News
- BusinessAustralia biotech firm CSL says plasma business hit by Omicron, but demand robust
Australian biopharmaceutical firm CSL Ltd said first-half profit fell as the Omicron COVID-19 outbreak stopped people giving blood plasma, the core of its treatments, but declared a return to pre-pandemic collections, sending its shares soaring.
- MarketsSwiss stocks - Factors to watch on December 21
The Swiss blue-chip SMI was seen opening 0.9% higher at 12,705 points on Tuesday, according to premarket indications from bank Julius Baer .
- MarketsSwiss stocks - Factors to watch on December 20
The Swiss blue-chip SMI was seen opening 1.4% lower at 12,537 points on Monday, according to premarket indications from bank Julius Baer .
- MarketsSwiss stocks - Factors to watch on December 17
The Swiss blue-chip SMI was seen opening 0.44% lower at 12,735 points on Friday, according to premarket indications by bank Julius Baer .
- MarketsCSL, energy stocks drag Australia shares lower; tech rally limits losses
Australian shares slipped on Thursday, hit by health firm CSL Ltd and energy stocks, though gains in tech stocks tracking their U.S. peers helped limit losses.
- MarketsSwiss stocks - Factors to watch on December 16
Here are some of the main factors that may affect Swiss stocks on Thursday:
- MarketsCSL drags Australian shares lower, tech stocks rise
Australian shares inched lower on Thursday, as index heavyweight CSL led healthcare stocks lower following a discounted equity raising while tech heavyweights tracked their U.S. peers higher.
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,825.70 | -- |
| Copper | 693.65 | 0.33%Negative |
| Brent Crude Oil | 113.12 | -- |
| CBOT Soybeans | 1,609.00 | 0.99%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,911.74 | 3.06%Positive |
| Euro STOXX 50 | 3,533.17 | 2.82%Positive |
| FTSE 100 | 7,208.81 | 2.68%Positive |
| Nikkei 225 | 26,491.97 | 1.23%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes